novartis_microsoft_ai_still006_4k
Novartis
3 October 2019Big PharmaRory O'Neill

Novartis and Microsoft to collaborate on AI in medicine

Novartis has teamed with Microsoft to launch a new artificial intelligence (AI) innovation lab, which it says has the potential to “transform” and “reimagine” medicine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
21 January 2019   Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Big Pharma
17 October 2019   Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More on this story

Big Pharma
21 January 2019   Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Big Pharma
17 October 2019   Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More on this story

Big Pharma
21 January 2019   Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Big Pharma
17 October 2019   Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.